Please login to the form below

I have forgotten my password

cabozantinib

This page shows the latest cabozantinib news and features for those working in and with pharma, biotech and healthcare.

BMS eyes approval for second Opdivo combo in kidney cancer

plus tyrosine kinase inhibitor (TKI) Cabometyx (cabozantinib) compared to Pfizer’s older drug Sutent (sunitinib).

Latest news

Revenue growth at Ipsen numbs pain of palovarotene calamity

The French speciality drugmaker posted 2.58bn in sales for the full-year, up nearly 15%, thanks to another strong performance for cancer drugs Somatuline (lanreotide) and Cabometyx (cabozantinib) as well
Exelixis bounces back with new prostate cancer data

It is also testing cabozantinib in combination with Tecentriq in another setting – previously untreated HCC. ... Exelixis intends to file the cabozantinib/Tecentriq combination with the FDA for accelerated approval in metastatic CRPC by 2021.
Merck bulks up in cancer with $2.2bn Peloton buy

with Exelixis/Ipsen’s multikinase inhibitor Cabometyx (cabozantinib).
Merck’s Bavencio joins first-line kidney cancer face-off

Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’ Cabometyx (cabozantinib) as the
NICE clears Ipsen’s Cabometyx in first-line kidney cancer

access cabozantinib earlier in their treatment pathway.”.

More from news
Approximately 4 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

marketed product Cometriq (cabozantinib). ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... Also, the secondary endpoint, response rate, was higher and more significant with cabozantinib.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...